Black patients with acute myeloid leukemia (AML) experience higher mortality than White patients. We compared induction mortality, acuity of illness prior to chemotherapy, and insurance type between Black and White patients to assess whether acuity of presentation mediates the dis- The total effect of race on mortality during Induction I revealed a strong association (unadjusted HR 2.75, CI: 1.18, 6.41). Black patients had a significantly higher unadjusted risk of requiring ICUlevel resources within the first 72 hours after initial presentation (17% versus 11%; RR 1.52, CI:
The total effect of race on mortality during Induction I revealed a strong association (unadjusted HR 2.75, CI: 1.18, 6.41). Black patients had a significantly higher unadjusted risk of requiring ICUlevel resources within the first 72 hours after initial presentation (17% versus 11%; RR 1.52, CI:
1.04, 2.24). Mediation analyses revealed the indirect effect of race through acuity accounted for 61% of the relative excess mortality during Induction I. Publicly insured patients experienced greater induction mortality than privately insured patients regardless of race. Black patients with AML have significantly greater risk of induction mortality and are at increased risk for requiring ICU-level resources soon after presentation. Higher acuity amongst Black patients accounts for a substantial portion of the relative excess mortality during Induction I. Targeting factors affecting acuity of illness at presentation may lessen racial disparities in AML induction mortality.
| I N T R O D U C T I O N
Racial disparities in outcomes are well documented in many pediatric [1] [2] [3] and adult cancers 4 with Black patients consistently experiencing lower overall survival. Access to care and insurance status have been linked to higher mortality in many cancers. 5 Studies of adults with acute myeloid leukemia (AML) demonstrate lower rates of survival among Black patients compared with White patients 6 and pediatric studies have described higher mortality during the induction phase of therapy and lower overall survival among Black patients. [7] [8] [9] Although differences in pediatric AML outcomes by race have been documented, the pathways leading to these differences remain largely unexplored. Bhatia 10 postulated that advanced stage at diagnosis, health behaviors, lower socioeconomic status (SES), and differences in health insurance contribute to racial disparities in pediatric cancer survival. A recent study demonstrated that indeed lack of health insurance and lower SES are both associated with worse outcomes in children, adolescents, and young adults with AML in California. 11 Mediation analyses can elucidate causal intermediates and thus enable planning of targeted interventions to reduce disparities. 12, 13 We developed a mediation model to delineate the role of insurance type, SES, and acuity prior to chemotherapy initiation in racial disparities in AML induction mortality (Figure 1 ). Given the complexity of simultaneously modeling multiple associated mediators, we modeled acuity prior to chemotherapy as the primary mediator of mortality differences in Induction I by race while adjusting for SES and insurance type.
We tested this mediation model in a cohort of pediatric AML patients in the Pediatric Health Information Systems (PHIS) database.
PHIS includes detailed resource utilization data that allows for assessment of clinical acuity at presentation, as defined by the need for
Intensive Care Unit (ICU)-level resources within 72 hours of admission. [14] [15] [16] We hypothesized that Black children would have higher mortality than White children during the first 50 days following admission and that this difference would be attenuated during Induction II (or the first 100 days following admission). We further hypothesized that access to care, as measured by acuity of presentation prior to chemotherapy, mediates much of the mortality difference in Induction I. Finally, we posited that Black children would have higher resource utilization during Induction I than White children.
| M E T H O D S

| Data source
PHIS data included inpatient, emergency department, and observation unit information from over 40 not-for-profit, tertiary care pediatric hospitals. 17 Data included demographics, dates of service, discharge disposition, and daily inpatient billing data for medications, laboratory tests, imaging procedures, clinical services/procedures, and supplies. Data were de-identified at the time of submission and were exempt from IRB approval. Data were subjected to reliability and validity checks through a joint effort between the Children's Hospital Association, Truven Health Analytics, and participating hospitals.
| Study population
The study population of pediatric AML patients in PHIS was assembled using a validated process. 14 
| Race
The race of a patient, dichotomized as either Black or White, was identified by contributing hospitals and considered the primary 'exposure'
variable. Other racial groups were excluded because of modest sample sizes. Ethnicity was not evaluated as this information was missing in a substantial fraction of patients.
| Outcomes
The primary outcome of interest was inpatient mortality during Induction I. Inpatient deaths were identified based on discharge status for each hospitalization. Inpatient death during Induction II and ICU-level resource usage were secondary outcomes. ICU-level resources were defined by specific ICD-9-CM procedure codes or clinical resource utilization considered a priori as markers of ICU care rather than by physical location. 15 ICU-level resource requirements were evaluated by organ system as represented by vasopressor support, mechanical ventilation, renal replacement therapy, and leukapheresis, as well as the need for any of these therapies (versus none).
Daily utilization rates of antibiotic, antifungal, antiviral and vasopressor medications, parenteral nutrition, blood product replacement, and supplemental oxygen were determined from billing data. Binary indicators for each resource designated exposure on each inpatient day were generated and summed to obtain the total number of days exposed. Resource utilization rates were reported as days of use per 100 inpatient days.
| Proposed mediator
ICU-level resource utilization during the first 72 hours following admission for initial AML chemotherapy was examined as the potential mediator. This timeframe was chosen a priori to evaluate clinical acuity at presentation rather than acuity resulting from chemotherapy toxicity.
Acuity of presentation was dichotomized (<2 systems and 2 systems) 
| Statistical analyses
Distributions of patient characteristics were compared using chisquared tests. To evaluate potential confounding, each covariate was added independently to the crude models, and changes in the measure of association were assessed. A change greater than 10% was considered evidence of meaningful confounding; variables that produced such an effect size change were retained in final models.
Cox proportional hazards regression was used to estimate unadjusted and adjusted hazard ratios of induction mortality during Induction I and during Induction I and II. Generalized estimating equations with an exchangeable correlation matrix were used to obtain robust variance estimates to account for clustering by hospital. Log-binomial regression was used to estimate the risk ratios (RR) and 95% CIs comparing occurrence of ICU-level resource utilization.
Mediation analysis was performed to decompose the association of race on induction mortality into direct and indirect components. 24 The following are required for acuity of presentation to be considered a potential mediator: statistically significant associations between (1) race and acuity of presentation and (2) acuity of presentation and induction mortality, and (3) a non-null relationship between race and induction mortality. 24 First, the requisite component associations were assessed. Then, parameter estimates from the models for induction mortality conditional on acuity of presentation and race and for acuity of presentation conditional on race were combined to decompose the total effect of race on induction mortality into its indirect effect as mediated by acuity of presentation and its direct effect through other undefined pathways. 24 The proportion of the total effect mediated through acuity of presentation was computed on the difference scale from the estimates of the direct and indirect effects as HR direct 3
(HR indirect 2 1)/(HR direct 3 HR indirect 2 1). 24, 25 Kaplan-Meier curves and Cox regressions were used to explore the interaction on the additive scale between race and insurance type.
White patients with private health insurance were used as the reference group. Robust sandwich estimates of the variance-covariance matrix were used to account for clustering by hospital. The relative excess risk due to interaction was calculated to quantify interaction on the additive scale. 26 Only unadjusted results of the exploratory interaction assessment are presented due to small event numbers and concerns regarding overfitting.
Poisson regression models with inpatient days as offset were used to estimate adjusted rate ratios and 95% CI comparing resource utilization rates by race; a Pearson scale adjustment was used to correct for possible overdispersion. All analyses were performed using SAS (version 9.2, SAS Institute, Inc., Cary, NC). Table 1 lists patient characteristics for the study cohort. Sixteen percent of the study population was Black, 52% was male, and the median age was 9 years (interquartile range: 1-14 years). Distributions of sex and age did not differ by race. Black patients were significantly more likely than White patients to be publicly insured (55% versus 38%, P < 0.0001) and to be in the lowest income quartile (39% versus 22%,
The distribution of chemotherapy regimens administered in the second induction course did not differ by race (P 5 0.81). Pre-existing comorbidities as measured by ICD-9-CM codes in the year before the index AML admission could not be assessed because only 11% of the cohort was admitted to a PHIS hospital within that timeframe. 
| Early and overall induction mortality
| ICU-level resource utilization and acuity of presentation
Comparisons of ICU-level resource requirements by race are presented in 
| Mediation analysis
All three criteria were met to consider acuity of presentation as a potential mediator of the association between race and mortality dur- The role of acuity of presentation in mortality over the course of Induction I and II was also examined and the total effect of race is attenuated as are the component effects (Supporting Information eTable III). While there were many fewer deaths during Induction II, all of the deaths were amongst White patients.
| Adjustment for socioeconomic status and insurance type
When comparing the extremes of area-based median household income quartile (the highest versus lowest quartilies), they were neither significantly associated with mortality during Induction I (adjusted HR Abbreviations: RR, risk ratio; CI, confidence interval.
| Interactions between race and insurance type
The independent and joint effects of Black race and public insurance on mortality during Induction I were examined using White patients with private insurance as the reference group (Supporting Information eFigure 1A). The joint effect of Black race and public insurance (unadjusted HR 3.91, CI: 1.32, 11.6, P 5 0.01) was greater than expected based on the independent effects of Black race (unadjusted HR 1.37, CI: 0.17, 10.9, P 5 0.77) and public insurance (unadjusted HR 2.01, CI:
0.78, 5.18, P 5 0.15). The relative excess risk due to interaction was 1.53 (CI: 22.74, 5.80) with 39% of the joint effect due to interaction.
These results suggest that the absolute difference in mortality during Induction I between Black and White patients is larger among publicly insured children than privately insured children. 
| Resource utilization
| DISCUSSION
In a large nationally representative cohort, Black pediatric patients receiving standard AML chemotherapy experienced significantly greater inpatient mortality than White patients and 61% of this difference is explained by acuity of illness at presentation. From a methodological perspective, our approach of using resource utilization data in a mediation analysis enabled the determination of both the direct and indirect effects of race mediated through acuity of presentation while adjusting for area-based SES and insurance type as confounders.
Although the decreased survival of Black patients with AML relative to White patients has been described previously, 7-9 our data provide valuable insights into this disparity. Most notably, these data demonstrate an important role for presenting severity of illness and provide evidence that post-diagnostic supportive care does not substantially differ by race. Our findings also demonstrate that racial disparities persist despite reductions in mortality with the transition to ADE induction regimens. 27 The outcome gap observed previously within pediatric trials is seen in this cohort of patients unselected by clinical trial participation, which itself varies by race. [28] [29] [30] Moreover, our finding of increased acuity of presentation among Black patients is consistent with data from studies in pediatric and adult solid tumors showing Black patients present with more advanced disease. 1, [31] [32] [33] The novel finding of higher acuity of presentation among Black patients with AML provides direction for investigating this mortality disparity. Specifically, qualitative assessments of patient experiences leading up to and at time of AML diagnosis may uncover unknown barriers to accessing care and identifying signs and symptoms. PHIS resource utilization data do not allow for analyses using medication dose or hour-level timing of administration. Likewise, comorbidities could not be fully evaluated using the inpatient data available.
Furthermore, the use of zip code-derived household income provides only an approximation of SES, leading to the possibility of resonant confounding. Our mediation approach is very informative, but as with all mediation analyses, it does not address potential exposure-induced confounding of the acuity-mortality association, such as from SES or insurance type; however, given the small amount of change following adjustment, their role as confounders is likely limited.
This study represents a step toward understanding the complex factors underlying racial disparities in AML outcome and employs a methodological approach that is novel in this arena. However, additional studies are needed to extend this approach to outcomes beyond early mortality and to other possible mediators. Such analyses will require integration of different datasets 44 and large-scale cooperative studies across international borders to provide the more sophisticated understanding that is necessary for empirical interventions to address the disparities.
Racial disparities in early mortality among pediatric patients undergoing treatment for AML, may be explained in part by differences in acuity of illness prior to initiation of chemotherapy, which exceed the effects of SES and insurance type. Combined with the synergistic role of insurance type, these findings imply that access to care figures prominently in the greater early mortality among Black children than White children. Additional investigation into the events preceding and during presentation will help further elucidate what drives the differences in acuity, enabling the development of more targeted interventions to improve outcomes and eliminate this well-documented racial disparity.
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